Soligenix (NASDAQ: SNGX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.070 | -0.100 | -0.0300 | ||||
REV | 188.063K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Soligenix (NASDAQ: SNGX) through any online brokerage.
Other companies in Soligenix’s space includes: Allena Pharma (NASDAQ:ALNA), Cellectar Biosciences (NASDAQ:CLRB), Indaptus Therapeutics (NASDAQ:INDP), Abeona Therapeutics (NASDAQ:ABEO) and Sio Gene Therapies (NASDAQ:SIOX).
The latest price target for Soligenix (NASDAQ: SNGX) was reported by B. Riley Securities on Friday, December 4, 2020. The analyst firm set a price target for 4.00 expecting SNGX to rise to within 12 months (a possible 599.42% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Soligenix (NASDAQ: SNGX) is $0.5719 last updated Today at July 5, 2022, 5:36 PM UTC.
There are no upcoming dividends for Soligenix.
Soligenix’s Q2 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for Soligenix.
Soligenix is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.